Serotype-specific mucosal immune response and subsequent poliovirus replication in vaccinated children
- PMID: 12938203
- DOI: 10.1002/jmv.10480
Serotype-specific mucosal immune response and subsequent poliovirus replication in vaccinated children
Abstract
A total of 32 unimmunized children (median age 5 months) living in an orphanage in Minsk, Belarus, were vaccinated with three doses of oral poliovirus vaccine (OPV) with a 60-day interval between the doses. Blood samples were drawn before the immunizations and 45-50 days after each vaccine dose. Excretion of the vaccine viruses was followed by examining fecal specimens collected weekly after each vaccine dose. All children seroconverted by the second dose of OPV at the latest to all three serotypes of poliovirus but differences were seen regarding the intestinal responses. The strongest responses in both neutralizing antibodies and virus-binding IgA in fecal suspensions were seen toward poliovirus Type 2. Consistent with this, relatively little poliovirus Type 2 excretion was seen after the second and third doses of OPV as compared to that of poliovirus Type 1 or Type 3. The delayed development of functional intestinal immunity against the latter serotypes was associated with relatively weaker intestinal antibody responses compared to poliovirus Type 2. In the case of poliovirus Type 3, about 10% of children were still excreting the vaccine virus 9 weeks after administering the third dose. These results are consistent with epidemiological observations of the serotype-specific efficacy of OPV immunizations. The proportion of specimens showing nonpolio enteric viruses gradually increased through the 6-month study period. This may reflect the possibility that after the first dose of OPV, intensive replication of the vaccine viruses may out compete the nonpolio viruses in the intestines of the vaccinees or, alternatively, mask nonpolio viruses during the cell culture isolation procedure.
Copyright 2003 Wiley-Liss, Inc.
Similar articles
-
[The spread of the wild Poliovirus in the rural environment, the case of the Adzopé health district, Côte d'Ivoire].Bull Soc Pathol Exot. 2004 May;97(2):87-90. Bull Soc Pathol Exot. 2004. PMID: 15255346 French.
-
Oral iodine supplementation does not reduce neutralizing antibody responses to oral poliovirus vaccine.Bull World Health Organ. 1999;77(6):484-91. Bull World Health Organ. 1999. PMID: 10427933 Free PMC article. Clinical Trial.
-
Effect of different vaccination schedules on excretion of oral poliovirus vaccine strains.J Infect Dis. 2005 Dec 15;192(12):2092-8. doi: 10.1086/498172. Epub 2005 Nov 8. J Infect Dis. 2005. PMID: 16288372 Clinical Trial.
-
Global eradication of poliomyelitis: reinvent the wheel or use existing options effectively?Public Health Rev. 1993-1994;21(1-2):143-50. Public Health Rev. 1993. PMID: 8041881 Review.
-
Evidence for a causal association between oral polio vaccine and transverse myelitis: A case history and review of the Literature.J Paediatr Child Health. 2006 Apr;42(4):155-9. doi: 10.1111/j.1440-1754.2006.00840.x. J Paediatr Child Health. 2006. PMID: 16630313 Review.
Cited by
-
Expert review on poliovirus immunity and transmission.Risk Anal. 2013 Apr;33(4):544-605. doi: 10.1111/j.1539-6924.2012.01864.x. Epub 2012 Jul 15. Risk Anal. 2013. PMID: 22804479 Free PMC article. Review.
-
Assessing the impact of the Lebanese National Polio Immunization Campaign using a population-based computational model.BMC Public Health. 2017 Nov 25;17(1):902. doi: 10.1186/s12889-017-4909-0. BMC Public Health. 2017. PMID: 29178859 Free PMC article.
-
Shedding and reversion of oral polio vaccine type 3 in Mexican vaccinees: comparison of mutant analysis by PCR and enzyme cleavage to a real-time PCR assay.J Clin Microbiol. 2007 Aug;45(8):2419-25. doi: 10.1128/JCM.02268-06. Epub 2007 Jun 20. J Clin Microbiol. 2007. PMID: 17581940 Free PMC article.
-
Antigenic differences between AS03 adjuvanted influenza A (H1N1) pandemic vaccines: implications for pandemrix-associated narcolepsy risk.PLoS One. 2014 Dec 15;9(12):e114361. doi: 10.1371/journal.pone.0114361. eCollection 2014. PLoS One. 2014. PMID: 25501681 Free PMC article.
-
The evolution of Vp1 gene in enterovirus C species sub-group that contains types CVA-21, CVA-24, EV-C95, EV-C96 and EV-C99.PLoS One. 2014 Apr 2;9(4):e93737. doi: 10.1371/journal.pone.0093737. eCollection 2014. PLoS One. 2014. PMID: 24695547 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous